Computational Investigation of Ginsenoside F1 from *Panax ginseng* Meyer as p38 MAP Kinase Inhibitor: Molecular Docking and Dynamics Simulations, ADMET Analysis, and Drug Likeness Prediction.

Hae-Yong Noh, Muhammad Hanif Siddiqi, Sathishkumar Natatajan, Sera Kang, Sungeun Ahn, Yeon-Ju Kim and Deok-Chun Yang**

School of Biotechnology and Ginseng Bank, College of Life Sciences, Kyung Hee University, Yongin, 446-701, Republic of Korea.

*Corresponding Author: dcyang@khu.ac.kr

Running title: Panax ginseng and Parkinson's disease.

Please send us the Tables in word-format file and the Figures in JPG format

Abstract

Ginsenoside F1 is a biologically active compound identified potential from Korean *Panax ginseng* Meyer. In the present study, the potential targets of ginsenoside F1 were investigated by computational target fishing approaches including ADMET prediction, biological activity prediction from chemical structure, molecular docking, and molecular dynamics methods. Results were suggested to express the biological activity of ginsenoside F1 against p38 MAP kinase protein. The p38 MAP kinase protein is an important signal transducing enzyme involved in many cellular regulations, including signaling pathways, pain and inflammation. Numerous studies are shown that an abnormal activation of p38 MAP kinase leads to variety of diseases. The pharmacokinetic result proves that ginsenoside F1 can act like drug like molecule and non-toxic. In addition, molecular level interaction result of ginsenoside F1 with p38 MAP kinase active (binding) sites residues clearly defines inhibitory action of p38 MAP kinase. Further, molecular dynamics study also supported p38 MAP kinase and ginsenoside F1 structural stability. Findings from out

study will assist to discover the active drug like molecules from *Panax ginseng* with help of molecular modeling techniques.

Keywords: *Panax ginseng*; p38 MAP kinase inhibitor; G-F1; ADMET, Docking.

Introduction

Parkinson's disease (PD) is one of the major neurological disorder, which is severely reduce the dopaminergic neurons in substantia nigra of ventral midbrain due to the accumulation of insoluble of aggregated alpha-synuclein (α-Syn) in brain stem, spinal cord, and cortex. In the pathological condition of PD there is successive reduction of dopamine (DA) supply levels in the striatum that causes imbalance between neurotransmitters like acetylcholine and DA as well as degeneration of non-dopaminergic mechanism such as cholinergic, noradrenergic and serotonergic systems in Parkinson's disease (PD) person (1, 2). Probably numerous motor and non-motor characteristics symptoms including rigidity, tremors, depression, dementia, and sleep abnormalities are the consequence of deterioration of both dopaminergic and non-dopaminergic mechanism (3). The pathogenesis and etiology of PD are not entirely understood yet. Eventhough no model up to now has been able to elucidate all the pathological conditions of PD. However, the three main drug development advances, rotenone, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) are the most vital therapeutic agents for the management of PD as *in-vitro* and *in-vivo* (4). Dopamine transporter (DAT) produces free radicals and complex I inhibition by taken up 6-OHDA, 1-methyl-4-phenylpyridinium (MPP+) by the action of Monoamine oxidase B (MAOB) that can be accumulated by mitochondria (4). In recent decades, it has suggested that Mitogen-activated protein kinase (MAPK) pathways are the central inducers that transmit extracellular signals from the membrane to the nucleus in neurodegenerative disease and including PD and apoptosis.

Different extracellular stimuli such as environmental stressors, cellular injury, and inflammatory cytokines are responsible for activation of serine/threonine protein, which causing different neuronal cell death including differentiation, proliferation and apoptosis (5, 6). It has been suggested that the two vital members of the MAPK signaling cascades such as c-Jun N-terminal kinases (JNK) and p38 mitogen-activated protein kinases (p38MAPK) mediate neurodegeneration in PD and AD (7, 8). Several studies have found that activation of p38, a pivotal member of the mitogen-activated protein kinase (MAPK) super family plays a central role in the pathogenesis of neurological disorders such as Parkinson's disease, Alzheimer's disease and inflammatory diseases (9). It has also been reported that the p38 activation causes the activation of inflammatory cytokines such TNFα, IL-1β, cyclooxygenase (COX)-2, IL-6, IL-12 and IFN-γ, which play important roles in autoimmune, neurodegenerative and cardiovascular diseases (10-12).

Several *in-vivo* (Wistar rat, C57/BL6 mice,) and *in-vitro* (SH-SY5Y and PC12 cells) models might assist as valuable measurement tools for the evaluation and efficacy for development of novel therapeutic agents for treatments of PD. Widespread study of these *in-vitro* and *in-vivo* models have provided significant cellular agents of cell apoptosis comprising excitotoxicity, mitochondrial dysfunction, neuro-inflammation, nitric oxide and oxidative stress (13, 14).

Various therapeutic agents are used for enhancements in dopaminergic remedies and the development of non-dopaminergic medications to treat PD, however, they are associated with side effects. In this regard, natural compounds are potent sources for treatment and management of PD. Currently the root of Panax ginseng Meyer (P. ginseng) is used to treat human disorder as an oriental medicine. The major active components of P. ginseng are three types of saponins commonly referred to as "ginsenosides:" protopanaxadiol (PPD), protopanaxatriol (PPT), and

oleanolic acid (15). Many studies have revealed pharmacological and biological activities of different ginsenosides such as anti-oxidant, anti-inflammatory, and anti-proliferative effects (16). It has been reported that compound K and ginsenoside Rg3 have anti-tumor and anti-cancer activity (17, 18). Recently, we have reported that ginsenoside Rh1 and Rg5:Rk1 have anti-osteoporotic activity by elevating osteoblasts differentiation and mineralization in MC3T3-E1 cells (19, 20). In addition, it has been reported that ginsenoside Rh2 inhibits metabolic disorders like obesity through the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway (21). Ginsenoside F1 is a P. ginseng metabolite produced by enzymatic modification of ginsenoside Rg1, recently Tawab et al; reported that compound K, ginsenosides Rh1 and F1 were detected in the blood and urine of humans after oral administration of ginseng extract (22, 23). As several ginsenosides have been suggested for treatment of different diseases, however, there is no evidence published to support the efficacy of G-F1 in Parkinson's disease. Thus, to investigate the role of ginsenoside F1 in Parkinson's disease, we performed in silico docking of p38 MAPK with ginsenoside F1 and calculated their interaction properties including binding energy, hydrogen bonds and active site binding mode. We also investigated the molecular dynamics of protein-ligand complex in order to evaluate its binding stability. In addition, we predicted the absorption, distribution, metabolism, excretion, and toxicity (ADMET) of ginsenoside F1. The primary aims of this study were to determine the biological activities of ginsenoside F1 and its molecular interactions with p38 MAPK.

Materials and Methods

Preparation of Protein and ligand molecules

We retrieved the structure of G-F1 from our own in-house *P. ginseng* saponin database. Its two-dimensional (2D) structure was drawn using ACD/ChemSketch (http://www.acdlabs.com)

and converted to a three-dimensional (3D) structure by the OpenBabel program (24). We retrieved the p38 MAPK inhibitor SB203580 from the p38 MAPK crystal complex structure to use as the control ligand for docking simulation. Figure 1. shows the 2D structures of G-F1 and SB203580 ligand. These two compounds were energy-minimized using the 200 steps of steepest descent (25) followed by the conjugate gradients method (26) using the universal force field (UFF) (27) as carried out by the PyRx program (28).

ADMET screening for drug likeness

Lipinski's rule of five (29) was used to determine drug-likeness. This rule is based on the observation that most orally administered drugs have molecular weight less than 500, a distribution ratio less than 5, less than 5 hydrogen bond donors, and less than 10 hydrogen bond acceptors. The ADMET profile of G-F1 was determined studied using the Qikprop 3.0 module encoded by the Schrodinger program (http://www.schrodinger.com). This program generates both physicochemical and pharmacokinetically relevant properties based on the structure of G-F1. Qikprop 3.0 allows comparison of a particular molecule's properties with those of 95% of known drugs. The hepatotoxicity and CYP2D6 inhibition scores were calculated using the ADMET module available from the DS 2.5 program (http://accelrys.com). The ADMET prediction steps were followed from our previous publications (30).

In silico prediction of biological activity

We used the prediction of activity spectra for substances (PASS) online server (http://www.pharmaexpert.ru/passonline/) (31), which predicts pharmacological properties based on chemical structure, to predict G-F1 biological activity. PASS provides a list of biological

activity types for which the active (Pa) and inactive (Pi) probabilities are calculated. Pa and Pi values are independent and their values vary from 0 to 1.

Molecular docking simulation

Molecular docking studies were performed with Autodock 4.2 (32-34) using the Lamarckian Genetic Algorithm 4.2 scoring parameter (35). The X-ray crystal structure of p38 MAPK was obtained from the RCSB PDB Database (http://www.rcsb.org/pdb) as a PDB file (PDB ID: 1A9U) with a resolution of 2.50 Å (36). Figure 2. shows the 3D structure of p38 MAPK. The enzyme structure was co-crystallized with SB203580 inhibitor in 1A9U; polar hydrogen atoms and Kollman charges were added to perform docking studies. Then, SB203580 and water molecules were removed and polar hydrogen atoms were added. SB203580 has two hydrogen bond interactions with residues Lys53 and Met109 (37). These active sites are considered to be the most favorable for docking simulations. The best molecular interaction was identified based on binding orientation of p38 MAPK key residues and their corresponding binding affinity scores. The docking results of G-F1 with p38 MAPK were visualized using the DS 3.5 program; further 2D interactions were analyzed using the PoseView web-server (38, 39) (http://poseview.zbh.uni-hamburg.de/poseview) to determine their mode of interaction with pocket residues.

Molecular dynamics simulations

Molecular dynamics simulations were performed with a Gromacs96 43a2 force field (40) and a single-point-charge water model (41) using the Gromos 4.6 program (42). In this study, we performed molecular dynamics simulations for three structures, which include the apo form of p38 MAPK, the known inhibitor complex formed by p38 MAPK/SB203580, and the p38

MAPK/G-F1 complex. The Gromos program's utility pdb2gmx was used to generate p38 MAPK topology files; topology files for ligands G-F1 and SB203580 were created using the Dundee PRODRG2 server (43) (http://davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg). Each structure was neutralized by adding the appropriate ions (Na^+ or Cl^-), followed by canonical ensemble and isothermal-isobaric ensemble equilibration. Individual systems underwent 25-nanosecond production. The root mean square deviation (RMSD) and root mean square fluctuation (RMSF) values were calculated using the Gromos program utilities g_rms and g_rmsf. All molecular dynamics simulations were performed using the Intel® 2.93 GHz Xenon® CPU 5679 RHEL 6 server.

Result and discussion

Parkinson's disease is the most common neurodegenerative disease that effect thousands of people throughout the world. During Parkinson's disease, there is successive neurodegeneration and loss of neurons in the brain are responsible. Recently, it has been suggested that p38MAPK plays a significant role in hippocampal neurons apoptosis and cerebellar granule neurons, (44–46). Therefore, in this study, we investigated the in silico inhibitory activity of G-F1 by assessing the expression of p38MAPK. To our knowledge this is the first report showing G-F1 has strong inhibitory action on the expression of p38MAPK and may be acts as anti-Parkinson's disease-specific. Ginsenosides, the most active constituent of *Panax ginseng*, plays important role in the pharmacological action of ginseng. Modern studies demonstrate that these ginsenosides are distinctive triterpenoid dammarane saponins and have a valuable beneficial effect on the protection and stimulation for CNS-related diseased conditions, mainly PD. Though, these ginsenosides are being used for decades, however, their pharmacological action and molecular level activity is still unknown. P38, one of the most probable the therapeutic target of PD, and

the tested ginsenoside (G-F1) for neuroprotective behavior was selected for the current study. We examined the molecular interaction using in silico molecular docking to reveal the protein-ligand (p38-G-F1) interaction. The strength of the protein-ligand (p38-G-F1) interaction were determined by the binding free energy or docking score of the protein–ligand complex structure.

Screening pharmacological properties (ADMET properties)

In silico predictions have been used to determine ADMET descriptors such as serum protein binding capacity, blood-brain barrier crossing, central nervous system activity, and HERG K+ channel activity, apparent Caco-2, apparent MDCK, and skin permeability, percentage of human gastrointestinal absorption, hepatotoxicity, and CYP2D6 probability. We used Lipinski's rule of five to determine the drug-likeness of G-F1. By this rule, most orally administered drugs have molecular weight less than 500, a distribution ratio less than 5, less than 5 hydrogen bond donors, and less than 10 hydrogen bond acceptors. G-F1 had a molecular weight of 638.88 kda, a distribution ratio of 2.482, 7 hydrogen bond donors and 14 hydrogen bond acceptors. Although G-F1 did not obey Lipinski's rule of 5, these values fall within the accepted ranges of 95% of known drugs. Additionally, toxicity estimation is one of the most vital task in natural compound screening (47), thus we estimated hepatotoxicity descriptors (0 is non-toxic and 1 is toxic) for tested ginsenoside by using ADMET module accessible from DS 2.5. The detailed results of predicted ADMET values of G-F1 with acceptable range were shown in Table 1. At last, after this screening filter, we concluded that G-F1 has the capability to cross the BBB and act as potential therapeutic agents of PD treatment. Furthermore, the biological activity spectrum of G-F1 was predicted using the PASS program, which shows the probability of active (Pa) and the probability of inactive (Pi) properties. Pa and Pi range from 0 to 1. The predicted 28 properties of G-F1, along with Pa and Pi values, are shown in Table 2.

Molecular interaction studies

The p38 MAPK crystal structure was used to perform docking simulation using the Auto Dock 4.2 program. In this study we used SB203580 as a control molecule, which is a well-known drug for the inactivation and inhibition of p38 MAPK via its specific active sites including Lys 53 and Met 109. Figure 4. shows the RMSD of 0.98 Å between the docked and crystal conformations of SB203580, indicating the reliability of the Auto Dock 4.2 program in reproducing the experimentally observed binding mode for p38 MAPK inhibitors. The docking results were verified based on the binding energy and formation of hydrogen bonds with Lys 53 and Met 109. The interaction between G-F1 and p38 MAPK formed four hydrogen bonds (Figure 3.) with a binding energy of -7.32 kal/mol. The detailed docking results along with the control ligand are described in Table 3. The Lys 53 residue formed one hydrogen bond between the hydrogen and oxygen atoms of G-F1, with a hydrogen bond distance of 1.98 Å. The Met 109 residue involved two hydrogen bond interactions between the hydrogen and oxygen atoms of G-F1, with hydrogen bond lengths of 1.89 Å and 1.98 Å, respectively. The Asp 168 residue, another enzyme active site, was also involved in hydrogen bond formation (length 2.10 Å).

Structure stability refinement using molecular dynamics

In order to examine and refine the structural stability of p38 MAPK, three individual molecular dynamics simulations were performed on the apo form of p38 MAPK and its ligand complexes with SB203580 and G-F1. Figure 5A. shows that the RMSD against the backbone of each complex attained equilibrium around 1604 ps (p38 MAPK-SB203580), and 01438 ps (p38 MAPK-G-F1). After equilibration, each complex remained stable throughout the 25000 ps simulation time. The RMSF analysis of the p38 MAPK-G-F1 complex was performed through the entire simulation against Cα atoms. To analyze the trajectory files, the active sites of the p38

MAPK-G-F1 complex were compared with the p38 MAPK-SB203580 complex. Figure 5B. displays the RMSF values of each complex. Molecular dynamics analysis showed less fluctuation in the enzyme's binding to G-F1 than its binding to SB203580. Throughout the simulation, the MAPK-G-F1 binding orientation did not affect structural stability or residue-level fluctuations of Cα atoms. In current research, computer docking and molecular modeling techniques play a significant role in the drug discovery and development.

Summary

In conclusion, the ADMET and PASS results suggest that G-F1 is a non-toxic, drug-like compound with potential for p38 MAPK inhibition. In particular, the strong interaction between G-F1 and p38 MAPK involved four hydrogen bonds with two active sites (Lys 53, Met 109). Molecular dynamics simulation suggested that the specified change less obviously was observed at coupling G-F1, p38 MAPK active site residues. Importantly, the p38 MAPK-G-F1 binding orientation did not affect the enzyme's structural stability. Taken together, our results suggest that G-F1 has a potentially therapeutic role by inhibiting p38 MAPK.

Our study concludes that ginsenoside F1 will be a promising compound for the development of anti-Parkinson's therapeutic agents.

Acknowledgements

References

(1) Forno LS. Neuropathology of Parkinson's disease. *J. Neuropathol. Exp. Neurol*. (1996) 55: 259–72.

(2) Schapira AH, Bezard E, Brotchie J, Calon F Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U and Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. *Nat. Rev. Drug Discov*. (2006) 5: 845–54.

(3) Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F and Bezard E. Priorities in Parkinson's disease research. *Nat. Rev. Drug Discov*. (2011) 10: 377–93.

(4) Beal MF. Experimental models of Parkinson's disease. *Nat. Rev. Neurosci*. (2001) 2: 325–34.

(5) Herrera-Molina R, Flores B, Orellana JA and Bernhardi RV. Modulation of interferon-γ-c induced glial cell activation by transforming growth factor b1: a role for STAT1 and MA PK pathways. *J. Neurochem*. (2012) 123: 113–23.

(6) Cargnello M and Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. *Microbiol. Mol. Biol. Rev*. (2011) 75: 50–83.

(7) Um HS, Kang EB, Koo JH, Kim HT, Jin-Lee, Kim EJ, Yang CH, An GY, Cho IH and Cho JY. Treadmill exercise represses neuronal cell death in an aged transgenic mouse model of Alzheimer's disease. *Neurosci. Res*. (2011) 69: 161–73.

(8) Kim EK and Choi EJ. Pathological roles of MAPK signaling pathways in human disease. *Biochim. Biophys. Acta*. (2010) 1802: 396–405.

(9) Yasuda S, Sugiura H, Tanaka H, Takigami S and Yamagata K. p38 MAP kinase inhibitor s as potential therapeutic drugs for neural disease. *Cent. Nerv. Syst. Agents Med. Chem*. (2011) 11: 45-59.

(10) Dodeller F and Schulze-Koops H. The p38 mitogen-activated protein kinase signa ling cascade in CD4 T cells. *Arthritis Res. Ther*. (2006) 8: 205–16.

(11) Palladino MA, Bahjat FR, Theodorakis EA and Moldawer LL. Anti-TNF-α therap ies: The next generation. *Nat. Rev. Drug Discov*. (2003) 2: 736–46.

(12)   Ding C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthriti s and

acute coronary syndrome. *Curr. Opin. Investig. Drugs* (2006) 7: 1020–5.

(13)   Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R and Verna JM. Molecu-lar pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: co ntribution to the apoptotic theory in Parkinson's disease. *Prog. Neurobiol*. (2001) 65: 135 –72.

(14)   Singh S and Dikshit M. Apoptotic neuronal death in Parkinson's disease: involve ment of   nitric oxide. *Brain Res. Rev.* (2007) 14: 233–50.

(15)   Kwak YS, Park JD and Yang JW. Present and its prospect of red ginseng efficacy research. *Food Ind. Nutr.* (2003) 8: 30-7.

(16)   Han BH, Han YN and Woo LK. Studies on the anti-inflammatory glycosides of *Panax ginseng*. *J. Pharm. Soc. Korea*. (1972) 26: 129-36.

(17)   Wakabayashi C, Hasegawa H, Murata J and Saiki I. *In vivo* antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration. *Oncol. Res*. (1997) 9: 411-7.

(18)   Mochizuki M, Yoo YC, Matsuzawa K, Sato K, Saiki I, Tono-oka S, Samukawa K and Azuma I. Inhibitory effect of tumor invasion and metastasis by saponins, 20(R) - and 20(S)-ginsenoside-Rg3, or red ginseng. *Biol. Pharm. Bull*. (1995) 9: 1197-202.

(19)   Siddiqi MH, Siddiqi MZ, Ahn S, Kim YJ and Yang DC. Ginsenoside Rh1 induces mouse osteoblast growth and differentiation through the bone morphogenetic protein 2/ru nt-related gene 2 signaling pathway. *J. Pharm. Pharmacol*. (2014) 12: 1763-73.

(20)   Siddiqi MH, Siddiqi MZ, Ahn S, Kang S, Kim YJ, Karpagam V, Yang DU and Y ang DC. Stimulative effect of Ginsenosides Rg5:Rk1 on murine osteoblastic MC3T3-E1 cells.
Phytother. Res. (2014) 28: 1447-55.

(21)   Hwang JT, Kim SH, Lee MS, Kim SH, Yang HJ, Kim MJ, Kim MS and Kwon DY. Anti-   obesity effects of ginsenoside Rh2 are associated with the activation of A MPK signaling pathway in 3T3-L1 adipocyte. *Biochem. Biophys. Res. Commun*. (2007) 364: 1002–8.

(22)   Ko SR, Choi KJ, Uchida K and Suzuki Y. Enzymatic preparation of ginsenosides Rg2, Rh1, and F1 from protopanaxatriol type ginseng saponin mixture. *Planta Med.* (2003) 69: 285-6.

(23)   Tawab MA, Bahr U, Karas M, Wurglics M and Schubert-Zsilavecz M. Degradati on of   Ginsenosides in humans after oral administration. *Drug Metab. Dispos.* (2003) 31: 1065-71.

(24)   O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T and Hutchison GR. Ope n Babel: An open chemical toolbox. *J. Cheminform.* (2011) 3: 33.

(25)   Sterck HD. Steepest descent preconditioning for nonlinear GMRES optimization. *Numer. Linear Algebra Appl.* (2013) 20: 453-71.

(26)   Barzilai J and Borwein JM. Two-Point step size gradient methods. *IMA J. Numer. Anal.* (1988) 8: 141-8.

(27)   Rappe AK, Casewit CJ, Colwell KS, Goddard WA and Skiff WM. UFF, a full periodic ta ble force field for molecular mechanics and molecular dynamics simulations. *J. AM. Chem. Soc.* (1992) 114: 10024-35

(28)   Wolf LK. PyRx, C&EN (2009) 87: 31-48.

(29)   Lipinski CA, Lombardo F, Dominy BW and Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* (2001) 46: 3-26.

(30)   Karpagam V, Sathishkumar N, Sathiyamoorthy S, Rasappan P, Shila S, Kim YJ and Yan g DC.   Identification of BACE1 inhibitors from Panax ginseng saponins-An In silco approac h. *Comput.   Biol. Med.* (2013) 43: 1037-44

(31)   Poroikov VV, Filimonov DA, Ihlenfeldt WD, Gloriozova TA, Lagunin AA, Borodin YV, Stepanchikova AV and Nicklaus MC. PASS biological activity spectrum predictions in the enhan ced open NCI database browser. *J. Chem. Inf. Comput. Sci.* (2003) 43: 228-36.

(32)   Jones G, Willett P, Glen RC, Leach AR and Taylor R. Development and validation of a genetic algorithm for flexible docking. *J. Mol. Biol.* (1997) 267: 727-48.

(33)   Goodsell DS, Morris GM and Olson AJ. Automated docking of flexible ligands: applications of AutoDock. *J. Mol. Recognit.* (1996) 9: 1-5.

(34)   Rarey M, Kramer B, Lengauer T and Klebe G. A fast flexible docking method using an incremental construction algorithm. *J. Mol. Biol.* (1996) 261: 470-89.

(35)   Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK and Olson

AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J. Comput. Chem*. (1998) 19: 1639-62.

(36)   Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL and Goldsmith EJ. Structural basis of inhibitor selectivity in MAP kinases. *Structure* (1998) 6: 1117-28.

(37)   Stierand K and Rarey M. Drawing the PDB: protein–ligand complexes in two dimensions. *ACS Med. Chem. Lett*. (2010) 1: 540-5.

(38)   Stierand K and Rarey M. Poseview-molecular interaction patterns at a glance. *J. Cheminform.* (2010) 2: P50.

(39)   Christen M, Hunenberger PH, Bakowies D, Baron R, Burgi R, Geerke DP, Heinz TN, Kastenholz MA, Krautler V, Oostenbrink C, Peter C, Trzesniak D and van Gunsteren WF. The GROMOS software for biomolecular simulation: GROMOS05. *J. Comput. Chem*. (2005) 26: 1719-51.

(40)   Ljungh A, Moran AP and Wadström T. Interactions of bacterial adhesins with extracellular matrix and plasma proteins: pathogenic implications and therapeutic possibilities. *FEMS Immunol. Med. Microbiol*. (1996) 16: 117-26.

(41)   Berendsen HJC, Postma JPM, van Gunsteren WF and Hermans J. Interaction models for water in relation to protein hydration. B. Pullman (ed.). *Intermolecular Forces, Reidel, Dordrecht,* (1981) 41: 331-42.

(42)   Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE and Berendsen HJ. GROMACS: Fast, flexible, and free. *J. Comput. Chem*. (2005) 26: 1701-18.

(43)   Schüttelkopf AW and Van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallogr. D Biol. Crystallogr*. (2004) 60: 1355-63.

(44)   Mei Y, Yuan Z, Song B, Li D, Ma C, Hu C, Ching YP and Li M. Activating transcription factor 3 up-regulated by c-Jun NH(2)-terminal kinase/c-Jun contributes to apoptosis induced by potassium deprivation in cerebellar granule neurons. *Neurosci*. (2008) 151: 771–9.

(45)   Barone MC, Desouza LA and Freeman RS. Pin1 promotes cell death in NGF dependent neurons through a mechanism requiring c-Jun activity. *J. Neurochem.* (2008) 106: 734–45.

(46)   Cai W, Rudolph JL, Sengoku T and Andres DA. Rit GTPase regulates a p38 MAPK dependent neuronal survival pathway. *Neurosci. Lett*. (2012) 531: 125–30.

(47)   Mohan CG, Gandhi T, Garg D and Shinde R. Computer-assisted methods in chemical Toxicity prediction. *Mini-Rev. Med. Chem*. (2007) 7: 499–507.